Xenon Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update
XEN1101 Phase 3 program launched with initiation of X-TOLE2 clinical trial Strong financial position of approximately $752 million to fully support XEN1101 Phase 3 program development and expected cash runway into 2026 Conference call at 4:30 pm ET today …